The US Food and Drug Administration in a 2 August final rule broadened the benchmarks for what can be considered evidence for intended use of a device or drug, going against an industry that wanted a more narrow approach focused on a firm’s promotional claims.
The rule puts a cap on five years of drama on the issue of intended use that began in 2015...